Hematology Department, Champalimaud Center for the Unknown, Lisbon 1400-038, Portugal.
Immunology Department, Nova Medical School, Nova University of Lisbon, Lisbon 1169-056, Portugal.
J Immunol. 2018 Mar 15;200(6):1957-1963. doi: 10.4049/jimmunol.1701271.
The immunoregulatory and anti-infective properties of normal circulating polyclonal Abs have been exploited for the therapeutic purposes in the form of IVIG as well as several hyperimmune globulins. Current knowledge on the therapeutic use of normal Igs is based on the discoveries made by several pioneers of the field. In this paper, we review the evolution of IVIG over the years. More importantly, the process started as an s.c. replacement in γ globulin-deficient patients, underwent metamorphosis into i.m. Ig, was followed by IVIG, and is now back to s.c. forms. Following successful use of IVIG in immune thrombocytopenic purpura, there has been an explosion in the therapeutic applications of IVIG in diverse autoimmune and inflammatory conditions. In addition to clinically approved pathological conditions, IVIG has been used as an off-label drug in more than 100 different indications. The current worldwide consumption of IVIG is over 100 tons per year.
正常循环的多克隆抗体的免疫调节和抗感染特性已被开发用于治疗目的，形式为 IVIG 和几种高免疫球蛋白。目前关于正常 Ig 的治疗用途的知识是基于该领域的几位先驱的发现。在本文中，我们回顾了多年来 IVIG 的发展。更重要的是，这个过程始于对γ球蛋白缺乏症患者的皮下替代治疗，经历了肌内 Ig 的转变，随后是 IVIG，现在又回到了皮下形式。在 IVIG 成功用于免疫性血小板减少性紫癜后，IVIG 在多种自身免疫和炎症性疾病中的治疗应用呈爆炸式增长。除了临床批准的病理状况外，IVIG 还被用作 100 多种不同适应症的标签外药物。目前，全球 IVIG 的年消耗量超过 100 吨。
